Antengene and Merck (MSD) have entered into a global clinical collaboration to assess the former’s oral small molecule CD73 inhibitor, ATG-037 as a monotherapy and along with the latter’s Keytruda (pembrolizumab) in a Phase I study.

Under the alliance, the companies will carry out an open-label, multicentre Phase I dose-finding study (STAMINA-001 study) of ATG-037 along with Keytruda in locally advanced or metastatic solid tumour patients.

The STAMINA-001 study’s primary objective is to assess the tolerability and safety of ATG-037 as a single agent and along with Keytruda for determining the suitable dose for Phase II studies.

Characterisation of the pharmacology and evaluation of ATG-037’s preliminary efficacy include the secondary objectives of the trial.

As per the terms of the deal, Antengene will be responsible for conducting the study, while MSD will supply Keytruda for the trial’s combination portions.

Antengene chief medical officer Dr Amily Zhang said: “Antengene believes that cancer treatments involving the rational combination of immuno-oncology drugs and targeted therapies may offer the greatest opportunity for substantial advances in treatment outcomes for patients with cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The mechanism of action of ATG-037 in inhibiting adenosine-generating CD73 is expected to reverse an immunosuppressed tumour microenvironment, thereby creating potential additive benefit with multiple immuno-oncological approaches.

“We hope this collaboration will generate data that allows us to proceed to later phase studies in patients with a variety of cancers, with potential for significant positive impact on treatment outcomes.”

The company stated that ATG-037 has been approved to enter trials in Australia and China.

Currently, the enrolment of participants for the Phase I study of ATG-037 is underway in Australia.